NCT03265366

Brief Summary

The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 29, 2017

Completed
16 days until next milestone

Study Start

First participant enrolled

September 14, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 24, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 24, 2020

Completed
Last Updated

February 10, 2022

Status Verified

February 1, 2022

Enrollment Period

2.4 years

First QC Date

August 25, 2017

Last Update Submit

February 9, 2022

Conditions

Keywords

Ultrashort echo time magnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

  • Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions)

    Measured by a kappa test

    Day 0

Study Arms (2)

ABPA

EXPERIMENTAL

15 patients with ABPA

Device: MRIDevice: CT scan (standard reference)

Severe asthma

ACTIVE COMPARATOR

12 patients with severe asthma

Device: MRIDevice: CT scan (standard reference)

Interventions

MRIDEVICE

It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.

ABPASevere asthma

It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.

ABPASevere asthma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • study patients have a diagnosis of ABPA
  • control patients have severe asthma
  • All the patients are ≥ 18 years old, have social security care, signature of consent form

You may not qualify if:

  • cystic fibrosis
  • other type of aspergilloses
  • contraindication for MRI
  • woman without effective contraception

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Bordeaux

Pessac, 33604, France

Location

MeSH Terms

Conditions

Aspergillosis, Allergic Bronchopulmonary

Interventions

Tomography, X-Ray ComputedReference Standards

Condition Hierarchy (Ancestors)

Pulmonary AspergillosisAspergillosisMycosesBacterial Infections and MycosesInfectionsLung Diseases, FungalRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Image Interpretation, Computer-AssistedDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisRadiographic Image EnhancementImage EnhancementPhotographyRadiographyTomography, X-RayTomographyWeights and MeasuresInvestigative Techniques

Study Officials

  • Julie MACEY, MD

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2017

First Posted

August 29, 2017

Study Start

September 14, 2017

Primary Completion

January 24, 2020

Study Completion

January 24, 2020

Last Updated

February 10, 2022

Record last verified: 2022-02

Locations